Note 9 - Business Segment Information (Tables)

6 Months Ended

Jun. 30, 2022

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three months ended June 30,						Six months ended June 30,
	2022			2021			2022			2021
Revenue
BioLargo corporate	$	—		$	—		$	2		$	7
ONM		700			318			1,300			638
BLEST		670			266			1,213			654
Water		—			—			—			9
Clyra Medical		6			—			17			114
Intersegment revenue		(53	)		(120	)		(245	)		(387	)
Total	$	1,323		$	464		$	2,287		$	1,035
Operating income (loss)
BioLargo corporate	$	(923	)	$	(937	)	$	(2,143	)	$	(1,860	)
ONM		11			(107	)		18			(283	)
Clyra Medical		(256	)		(300	)		(496	)		(739	)
BLEST		56			(190	)		21			(373	)
Water		(209	)		(168	)		(431	)		(305	)
Total	$	(1,321	)	$	(1,702	)	$	(3,031	)	$	(3,560	)
Interest expense
BioLargo corporate	$	(6	)	$	(51	)	$	(12	)	$	(106	)
Clyra Medical		(9	)		(38	)		(16	)		(76	)
Total	$	(15	)	$	(89	)	$	(28	)	$	(182	)
Research and development expense
BioLargo corporate	$	(165	)	$	(209	)	$	(430	)	$	(545	)
Clyra Medical		(26	)		(6	)		(42	)		(33	)
BLEST		(80	)		(123	)		(188	)		(228	)
Water		(130	)		(138	)		(327	)		(257	)
Intersegment R&D		46			120			240			380
Total	$	(355	)	$	(356	)	$	(747	)	$	(683	)

As June 30, 2022	BioLargo		ONM		Clyra		BLEST		Water		Elimination			Total
Tangible assets	$	631	$	723	$	799	$	641	$	179	$	(19	)	$	2,954
Right of use		179		—		—		211		—		—			390
Investment in South Korean joint venture		33		—		—		—		—		—			33
Total		843		723		799		852		179		(19	)		3,377

As of December 31, 2021	BioLargo		ONM		Clyra		BLEST		Water		Elimination			Total
Tangible assets	$	690	$	451	$	832	$	445	$	152	$	(47	)	$	2,522
Right of use		222		—		—		231		—		—			453
Investment in South Korean joint venture		48		—		—		—		—		—			48
Total		960		451		832		676		152		(47	)		3,023